CLCM
PTLA

Crawford Lake Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Crawford Lake Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,400
Closed -$2.66M – 145
2017
Q2 		$2.66M Buy
+47,400
New +$1.9M 0.59% 52

Other funds holding PTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Crawford Lake Capital Management's PTLA Position: Q3 2017 in Review

Crawford Lake Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 47,400 shares — an estimated $2.66M sold.

Crawford Lake Capital Management first reported a position in PTLA in Q2 2017 and held it in 1 quarter. The position peaked at $2.66M in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

  • Crawford Lake Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Crawford Lake Capital Management sold 47,400 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $2.66M.
  • Crawford Lake Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Crawford Lake Capital Management's Portola Pharmaceuticals, Inc. position peaked at $2.66M in Q2 2017.
  • 221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Crawford Lake Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.